|
|
Article: BIOTECH COMPANY GETS CAPITAL RENOVAR IS TESTING EARLY WARNING OF TRANSPLANT REJECTIONS.(Business)
- Article from:
- The Wisconsin State Journal (Madison, WI)
- Article date:
- August 12, 2000
CopyrightCOPYRIGHT 2000 Capital Newspapers. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
A Madison biotechnology company that hopes to help transplant patients is getting a financial boost.
Renovar just began operations last month, the outgrowth of UW-Madison research, and already it has landed a $500,000 stock purchase from Fujisawa Investments for Entrepreneurship. The Evanston, Ill., venture capital firm is an arm of a major Japanese drug company, Fujisawa Pharmaceutical Co.
``In the transplant field, Fujisawa has a very dominant position,'' said UW-Madison transplant surgeon Dr. Stuart Knechtle, Renovar co-founder and chief scientific officer.
Renovar is testing a method to see if a patient is about to reject a transplanted ...
Related newspaper, magazine, and journal articles:
|
|
Article: Data on sports medicine detailed by B. Knechtle and ...
Health & Medicine Week;
May 25, 2009 ;
572 words
... ... Delta skeletal muscle mass," wrote B. Knechtle and colleagues (see also Sports Medicine ... reduction in skeletal muscle mass." Knechtle and colleagues published their study ... additional information, contact B. Knechtle, Gesundheitzentrum, Vadianstr 26 ...
|
|